Clinical Trials Browser

Urinary Bladder Neoplasms, Carcinoma, Hepatocellular, Mesothelioma, Ovarian Neoplasms, Paraganglioma, Pheochromocytoma, Sarcoma, Stomach Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma

NCT04924075 2026-05-11

MK-6482-015

Phase 2 Recruiting

322 enrolled 1 FDA

CNSEndocrine

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT03206060 2026-04-24

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

Phase 2 Recruiting

130 enrolled

CNSEndocrineNET

Hypertension, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT07282587 2026-02-27

Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma

Phase 2 Recruiting

90 enrolled

CNSEndocrine

Paraganglioma

NCT07167329 2025-09-11

BELIEVE-VHL

Phase 2 Recruiting

100 enrolled

CNSEndocrineGenitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma, Neuroectodermal Tumors, Primitive, Hemangioblastoma

NCT06683846 2025-08-24

Ivonescimab in the Treatment of Multiple Advanced Tumors

Phase 2 Recruiting

400 enrolled

CNSDermatologicEndocrineGenitourinarySarcoma

Urachal cancer, Carcinoma, Carcinoma, Basal Cell, Carcinoma, Transitional Cell, Kidney Neoplasms, Paget Disease, Extramammary, Paraganglioma, Penile Neoplasms, Pheochromocytoma, Prostatic Neoplasms, Rhabdomyosarcoma, Sarcoma, Angiomyolipoma, Carcinoma, Neuroendocrine, Perivascular Epithelioid Cell Neoplasms

NCT06045260 2024-08-13

LUFOR

Phase 2 Recruiting

100 enrolled

CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

Clinical Trials

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

MK-6482-015

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma

BELIEVE-VHL

Ivonescimab in the Treatment of Multiple Advanced Tumors

LUFOR